



Please type a plus sign (+) inside this box →

+

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/616,101	
		Filing Date	July 8, 2003	
		First Named Inventor	LUO, YING	
		Group Art Unit	1642	
		Examiner Name		
Total Number of Pages in This Submission		7	Attorney Docket Number	RIGL-010CIP3
ENCLOSURES (check all that apply)				
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)		<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Copies from parent of Form PTO/SB/08A 2. Postcard
Remarks				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT				
Signing Attorney/Agent (Reg. No.)	JAMES S. KEDDIE, PH.D., 48.920 BOZICEVIC, FIELD & FRANCIS LLP			
Signature				
Date	October 30, 2003			
EXPRESS MAIL LABEL NO. EV333998914US				

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV333998914US

INFORMATION DISCLOSURE STATEMENT Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	RIGL-010CIP3
	First Named Inventor	LUO, YING
	Application Number	10/616,101
	Confirmation No.	5361
	Filing Date	July 8, 2003
	Group Art Unit	1642
	Examiner Name	
Title: "TANKYRASE H, COMPOSITIONS INVOLVED IN THE CELL CYCLE AND METHODS OF USE"		

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.


All of the references identified herein were disclosed in parent application serial number 09/843,159, filed 4/25/2001 and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. § 102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. RIGL-010CIP3 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: October 30, 2003

By: 
James S. Keddie, Ph.D.
Registration No. 48,920

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	09/843,159
Filing Date	April 25, 2001
First Named Inventor	LUO, Ying
Art Unit	1652
Examiner Name	RAO, M.
Attorney Docket Number	A-68292-2/RMS/DHR; 467802-217

Sheet 1 of 2

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A4	US- 6,455,290 B1	09/24/2002	Berthelsen et al.	
	A5	US- 6,277,613 B1	08/21/2001	De Lange et al.	
	A6	US- 6,387,902 B1	05/14/2002	Zhang et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

COPY

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
	B8	WO	01/04326 A1	01/18/2001	Berthelsen et al.		<input type="checkbox"/>	<input type="checkbox"/>
	B9	WO	00/77225 A1	12/21/2000	Chi et al.		<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number

09/843,159

Filing Date

April 25, 2001

First Named Inventor

LUO, Ying

Art Unit

1652

Examiner Name

RAO, M.

Sheet

2

of

2

Attorney Docket Number

A-68292-2/RMS/DHR; 467802-217

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	C27	DECKER, P. et al., "An Improved Nonisotopic Test to Screen a Large Series of New Inhibitor Molecules of Poly(ADP-ribose) Polymerase Activity for Therapeutic Applications," Clinical Cancer Research, 5:1169-1172, May 1999.	<input type="checkbox"/>	<input type="checkbox"/>
	C28	RANKIN, P.W. et al., "Quantitative Studies of Inhibitors of ADP-ribosylation <i>in Vitro</i> and <i>in Vivo</i> ," J. Biol. Chem., 264(8):4312-4317, March 1989.	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

COPY

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

开

COPY

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/843.159
--------------------	------------

Filing Date	April 25, 2001
--------------------	----------------

First Named Inventor	Luo
----------------------	-----

Group Art Unit	1653
----------------	------

Examiner Name	Unknown
---------------	---------

Attorney Docket Number	A-68292-2/RMS/DHR
------------------------	-------------------

Sheet	1	of	3
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
--------------------	--	-----------------	--


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



COPY

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/843,159
				Filing Date	April 25, 2001
				First Named Inventor	Luo
				Group Art Unit	1653
				Examiner Name	Unknown
Sheet	2	of	3	Attorney Docket Number	A-68292-2/RMS/DHR

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Smith et al., "Tankyrase, a poly (ADP-ribose) polymerase at human telomeres," Science, 282(5393):1484-1487 (November 1998).	
	C2	Mera, S., "The role of telomeres in aging and cancer," Br J Biomed Sci, 55(3):221-225 (September 1998).	
	C3	Lux et al., "Analysis of cDNA for human erythrocyte ankyrin indicates a repeated structure with homology to tissue-differentiation and cell-cycle control proteins," Nature, 344(6261):36-42 (March 1990).	
	C4	Bryan et al., "Telomerase and the maintenance of chromosome ends," Curr Opin Cell Biol, 11(3):318-324 (June 1999).	
	C5	Hiyama et al., "Overexpression of human telomerase RNA is an early event in oesophageal carcinogenesis," Virchows Arch, 434(6):483-487 (June 1999).	
	C6	Krejc, K., "An in situ study of variant telomeric repeats in human chromosomes," Genomics, 58(2):202-206 (June 1999).	
	C7	Holt et al., "Role of telomerase in cellular proliferation and cancer," J Cell Physiol, 180(1):10-18 (July 1999).	
	C8	Tan, Z., "Intramitotic and intraclonal variation in proliferative potential of human diploid cells: explained by telomere shortening," J Theor Biol, 198(2):259-268 (May 1999).	
	C9	Zhu et al., "Chromosomal mapping of the tankyrase gene in human and mouse", Genomics 57:320-321 (1999)	
	C10	Daly, "The Grb7 Family of Signalling Proteins," Cell. Signal 10(9):613-618 (1998)	
	C11	Janes, et al., "Structural Determinants of the Interaction between the erbB2 Receptor and the Src Homology 2 Domain of Grb7," J Biol Chem 272(13):8490-8497 (1997)	
	C12	Daly, "Take Your Partners, Please - Signal Diversification by the erbB Family of Receptor Tyrosine Kinases," Growth Factors 16:255-263 (1999)	
	C13	Bowie et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," Science 247:1306-1310 (1990)	
	C14	Burgess et al., "Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue," J Cell Bio. 111(5 pt 1):2129-2138 (1990)	
	C15	Scott et al., "The Pendred syndrome gene encodes a chloride-iodide transport protein," Nat Genet 21(4):440-443 (1999)	
	C16	Bork, P., "Powers and Pitfalls in sequence analysis: the 70% hurdle," Genome Res 10(4):398-400 (2000)	
	C17	Reiger et al., Glossary of Genetics and Cytogenetics, Classical and Molecular 4th Ed., Springer-Verlay, Berlin, pp. 17-18 (1976)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box ☐



PTO/SB/8B (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known		
				Application Number	09/843,159	
Sheet		3	of	3	Filing Date	April 25, 2001
					First Named Inventor	Luo
					Group Art Unit	1653
					Examiner Name	Unknown
					Attorney Docket Number	A-68292-2/RMS/DHR

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C18	Lazar, et al., "Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities," Mol Cell Biol 8(3):1247-1252 (1988)	
	C19	Harris et al., "Polycystic kidney disease. 1: Identification and analysis of the primary defect," J Am Soc Nephrol 6(4):1125-1133 (1995)	
	C20	Ahn, et al., "The structural and functional diversity of dystrophin," Nat Genet 3(4):283-291 (1993)	
	C21	Cawthon et al., "cDNA sequence and genomic structure of EV12B, a gene lying within an intron of the neurofibromatosis type 1 gene," Genomics 9(3):446-460 (1991)	
	C22	Database SWALL:CGA1_XENLA, accession P18606 (Nov. 1990), Cyclin A1	
	C23	Database SWALL:CGB1_XENLA, accession P13350 (Jan 1990), G2/Mitotic-specific Cyclin B1	
	C24	Database SWALL:CGB1_HUMAN, accession P14635 (Apr 1990), G2/Mitotic-specific Cyclin B1	
	C25	Database EMBL:MMAA24592, accession AA124592 (Nov 1996), mp86g12.r1 Soares_thymus_2NbMT Mus musculus cDNA clone similar to gb:M25753 G2/Mitotic-specific Cyclin B1 (Human)	
	C26	Database EMBL:HSZZ78609, accession AA373339 (Apr 1997), EST85503 HSC172 cells I Homo sapiens cDNA 5' end similar to cyclin B, mRNA sequence	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.